Results 201 to 210 of about 337,841 (333)

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai   +4 more
wiley   +1 more source

Quiz (Electrocardiogram)

open access: yesJournal of the Practice of Cardiovascular Sciences, 2016
Neeraj Parakh, Sandeep Singh
doaj   +1 more source

Developing the Inpatient Mental Health Pharmaceutical Assessment and Care Tool (IMPACT) for use by UK mental health pharmacy teams—a modified Delphi study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To develop an evidence‐ and consensus‐based patient prioritization tool for use by UK mental health inpatient pharmacy teams. Methods A modified‐Delphi technique was used to obtain experts' agreement on the content, design and practical use of the patient prioritization tool.
Fatima Q. Alshaikhmubarak   +3 more
wiley   +1 more source

Electrocardiogram quiz

open access: yesJournal of the Practice of Cardiovascular Sciences, 2015
Praloy Chakraborty
doaj   +1 more source

Home - About - Disclaimer - Privacy